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1. Introduction 
One in six men in the U.S. will be diagnosed with prostate cancer in his lifetime; however, 
only one in 35 men will die from the cancer.1 As prostate-specific antigen (PSA) screening 
has become widespread, about 90 percent of patients are diagnosed with localized prostate 
cancer which will not lead to death in the majority of patients.2 As a result, over treatment of 
localized prostate cancer (LPC) has been an increasing concern. 3 However, prostate cancer 
is the second most common cause of cancer-related death in U.S. men, after lung cancer. 
Therefore not treating aggressive cancers which are detected early carries a grave risk.  
Treatment of localized cancer by surgery or radiotherapy can be curative; however, in about 
one-half to three-fourths of patients, the risk of death from screening-detected prostate cancer 
is very low, even if they choose observation. 4,5 A large U.S. retrospective study found that 
about 20 percent of low-risk patients who chose observation died from prostate cancer over 20 
years of follow-up.6 A Swedish randomized controlled trial also found a survival benefit after 
eight years of treatment in low-risk patients.7 However, patients in both of these studies had 
higher-stage cancer at diagnosis (i.e., their cancer was clinically diagnosed and was not 
detected by PSA screening). The Swedish trial also found that prostate cancer–specific mortal-
ity was only 2.4 percent at 10 years in low-risk patients who were randomized to active 
surveillance.8 A large study of 44,630 low-risk U.S. patients found a survival benefit of 
treatment, 9 but only 2.1% of the patient sample had died because of prostate cancer. 
Treatment is associated with urinary, sexual, and bowel dysfunction, and enhances the 
quality-adjusted survival of low-risk patients by only 1.2 months. 10 Five years after 
treatment in 3,533 patients, 79.3% of surgery patients and 63.5% of radiotherapy patients 
had erectile dysfunction, 15% of surgery patients and 4% of radiotherapy patients had at 
least frequent urinary leakage, and 19% of surgery patients and 29% of radiotherapy 
patients had bowel urgency.11 Side effects are unpredictable and vary very widely,12 and 
decisional regret is common.13 In addition, the cost of each potentially unnecessary 
prostatectomy or radiation treatment was about $10,000 to $25,000 in 2000 dollars. 14 Despite 
these concerns, about 94 percent of patients with localized prostate cancer choose 
treatment.15 In patients treated from 2000 to 2002, the rate of overtreatment (i.e., treatment in 
low-risk patients) was estimated to be about 55 percent.16   
Under-treatment of localized prostate cancer has also been a concern for over two decades. 
The incidence and mortality of the cancer are two to three times higher in black men.17 
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However, black and Hispanic men are more likely to be monitored instead of receiving 
treatment, possibly because they are more likely to present late, have poorer access to care, 
and sometimes a cultural preference for conservative treatment but many of these factors 
are not well evidenced.18 
Few randomized controlled trials have compared outcomes of different treatments for 
localized prostate cancer. A survey of 504 urologists and 559 radiation oncologists found 
that for the same hypothetical patient, 93 percent of urologists would recommend surgery, 
and 72 percent of radiation oncologists would recommend radiotherapy. 19 Although 
treatment of localized prostate cancer is unlikely to improve the survival of low-risk patients 
and has potentially negative effects on health-related quality of life, about 70 to 90 percent of 
patients choose a treatment during the first visit to a urologist after a positive biopsy.20 
In our survey of 184 men with newly diagnosed prostate cancer, more than one-half 
significantly overestimated the survival benefit of treatment. 21  Education, income, and 
health literacy did not affect the results; 60 percent of the survey respondents were college 
educated and had an annual income more than $50,000, and more than 90 percent had at 
least a ninth-grade health literacy. 22 Although these patients had been counseled by their 
urologists and had already elected treatment or observation, more than 50 percent 
incorrectly answered more than one-half of the 18 items in a questionnaire designed to test 
their knowledge, understanding, and judgment about the advantages and disadvantages of 
treatment options for prostate cancer.  This questionnaire22 can be used to identify patients 
who need further counseling about treatment choices.  
Over-, and Under-treatment occur because without the use of guidelines, it is extremely 
difficult for even the most intelligent LPC patient to make a good decision. Patients must 
choose from treatments with marginally different HRQOL outcomes, and without clear 
numerical probabilities of the frequency, severity, and duration of side effects. Finding the 
HRQOL outcome that can best match the patient’s preference can eclipse the bigger question 
of whether any treatment will enhance survival. Urologists are unsure too, which is reflected 
in their need to develop newer nomograms to predict survival even though 40 nomograms 
already exist. 23 Most urologists recommend definitive treatment for low risk young patients. 24 
Observation is inappropriate in many patients, and until better evidence is obtained, a 
balanced decision-aid with numerical probabilities is recommended. 25 This could be very 
difficult, given that for LPC patients, urologists have more than 69 tools to predict prognosis, 26 
and more than 800 articles 27 about HRQOL outcomes have been reported.  
Dahm et al 83 have suggested that such a complex decision should not be left to expert 
opinion alone, and that national guidelines can help in preventing over-, or under-treatment 
because guidelines are developed by panels of individuals who have the access and time to 
understanding and balance the available evidence. Guidelines aim to maximize both 
survival and HRQOL, are freely available on the Internet, are likely without much bias, and 
can give a point of reference from where patients may deviate by personal preference. 
However, in the literature, we found 160 articles with combinations of search terms and 
Medical Subject Headings including “prostate cancer, practice guidelines, NCCN, medical 
oncology/standards, evidence-based practice, urology/standards, and neoplasms/ 
therapy”. Except for a Japanese study on the outcomes of brachytherapy, 29 and a case report 
by Walsh 30 suggested that any named guideline was used in choosing a treatment for LPC. 
Our publication in 2010 was the first to show the use of guidelines; we have described a new 
method to estimate co-morbidity adjusted life expectancy that makes the use of guidelines 
feasible.31  
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Among ten guidelines published for choosing a treatment for LPC, the guideline by the 
National Comprehensive Cancer Network ( NCCN)32 was rated as the most evidenced-
based. 28 NCCN risk categories use the D’Amico criteria for survival prediction in LPC 
patients, 33 all NCCN guidelines require continuous review, and their recommendations are 
level 2A or better (either high level evidence or uniform consensus). The goal of NCCN 
guidelines is “to extend life expectancy while minimizing excess morbidity,” and the 
guidelines are based on the thinking that “despite differences in values, most patients 
would make the same choice.” An algorithm based on the NCCN guideline is presented in 
Figure 1. Four factors are used in determining the recommended treatment. These are: the 
cancer’s stage, its grade i.e, the Gleason score, the PSA level, and the estimated baseline co-
morbidity adjusted life expectancy of the patient. 
Stages T1 (not palpable) and T2 (palpable but limited to the prostate) are considered 
localized if there are no lymph nodes involved and no distant metastasis.  
The Gleason score is determined by adding the grades of the two most common histologic 
patterns seen in each biopsy core. Each pattern is scored from 1 to 5, with 5 being most 
poorly differentiated. For example, if grade 3 is the most common pattern and grade 4 is the  
 
Fig. 1a. 
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Fig. 1b. 
Fig. 1a and 1b. Algorithm based on guideline by National Comprehensive Cancer Network 
for selection of treatment for localized prostate cancer.  
next most common pattern, the Gleason score would be 7 (3+4). The most common grade is 
6, whereas grades 2 to 5 are uncommon. Grade 6 identifies a tumor with well-differentiated 
histology; grade 7 has intermediate differentiation; and grades 8 to 10 are the most poorly 
differentiated and have the worst prognosis. A grade 7 cancer is more aggressive if its scor-
ing is 4+3 instead of 3+4.  
PSA levels of 4 to less than 10 ng per mL, 10 to20 ng per mL (10 to 20 mcg per L), and 
greater than 20 ng per mL are associated with a low, intermediate, and high risk of prostate 
cancer recurrence after treatment, respectively. 
The factor of Comorbidity-adjusted Life Expectancy is particularly important because the 
number of comorbid diseases is the most significant predictor of survival after treatment of 
prostate cancer. 34 Prostate cancer  is usually slow growing, and the survival benefit of 
treatment may present only after 10 years or longer. This is the basis of the “10-year rule”: a 
patient with prostate cancer should be treated only if the patient has a comorbidity-adjusted 
life expectancy of at least 10 years. Age alone is not accurate in estimating life expectancy. 
To estimate comorbidity-adjusted life expectancy, the NCCN recommends the use of health 
status quartiles that match corresponding quartiles of life expectancy at each year of age. 
Tables 1a 35 and 1b 31 give a short patient-administered Charlson Comorbidity Index that can 
be used for a quick estimation of comorbidity-adjusted life expectancy.  
After deciding in favor of treatment, patients can choose between surgery and radiotherapy 
based on the side-effect profile of treatments.  A systematic review did not find any good-
quality head-to-head trials comparing surgery and radiotherapy. 36  The review found that   
surgery and external beam radiation therapy (EBRT) are equivalent in controlling the 
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cancer, especially if the baseline PSA level is greater than 10 ng per mL.36 Many trials 
studied biochemical progression but not long-term survival, and some trials were conducted 
before the advent of PSA testing. No trial has compared treatment outcomes by race or 
ethnicity, and most trials do not provide baseline racial characteristics.  Among patients in 
whom cancer was detected clinically (not by PSA screening), those who underwent radical 
prostatectomy (RP) had fewer prostate cancer–related deaths than patients who chose 
watchful waiting, although this benefit was limited to patients younger than 65 years. 36 
Patients who were operated on by surgeons who performed more than 40 RPs per year had 
fewer urinary adverse effects. Laparoscopic RP performed with or without the use of robotic 
technology is associated with less blood loss and shorter hospital stays, but all long-term 
outcomes are similar to open RP. In robotic laparoscopic RP, surgeons with more experience 
were more likely to achieve complete resection of the cancer.36 
 
Which medical problems have you had? 
 
Has this condition limited your 
activities, or do you need to take 
prescription medicine? 
 Yes No 
Inflammatory bowel disease O O O 
Liver disease O O O 
Stroke O O O 
Ulcer O O O 
Arthritis O O O 
Chest pain O O O 
Chronic lung disease O O O 
Depression O O O 
Diabetes mellitus O O O 
Heart attack O O O 
Heart failure O O O 
High blood pressure O O O 
Note: Inflammatory bowel disease, liver disease, stroke, and ulcers are scored as one disease each, 
regardless of severity. The remaining eight conditions are scored as one disease each only if the 
conditions limit the patient’s activity or require prescription medications.  
Table 1a. Patient-Administered 12-item Charlson Comorbidity Index  
EBRT is given over eight to nine weeks and is associated with more bowel adverse effects 
than surgery. Surgery is more difficult if cancer recurs after EBRT. The review found one 
trial in which proton therapy was more effective than EBRT. 36 In patients with low-risk 
cancer, brachytherapy using iodine-125 or palladium-103 pellet implantation is 
recommended as monotherapy.32 It is a preferred option in these patients because it controls 
the cancer as effectively as surgery or EBRT, and patients experience much less urinary 
incontinence and erectile dysfunction. Implantation may be difficult in patients who have 
bladder outlet obstruction or a very large or very small prostate, and in those who have had 
previous prostate surgery.  
Hormone therapy (also known as androgen deprivation therapy) as an adjunct to surgical 
treatment is discouraged in low-risk patients because it does not increase treatment effec-
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tiveness and is associated with gynecomastia and erectile dysfunction. 32, 36 Cryotherapy and 
high-frequency ultrasound are not recommended as routine monotherapies. 
 
Age (years) 
 
Life expectancy (years)
Top percentile of 
health (no disease)* 
Middle two 
percentiles of health 
(1 or 2 diseases)* 
Bottom percentile of 
health (3 or more 
diseases)* 
50 42.69 28.46 14.23 
51 41.43 27.62 13.81 
52 40.18 26.79 13.39 
53 38.94 25.96 12.98 
54 37.71 25.14 12.57 
55 36.49 24.33 12.16 
56 35.28 23.52 11.76 
57 34.06 22.71 11.35 
58 32.88 21.92 10.96 
59 31.69 21.13 10.56 
60 30.54 20.36 10.18 
61 29.4 19.6 9.8 
62 28.27 18.85 9.42 
63 27.16 18.11 9.05 
64 26.07 17.38 8.69 
65 25.00 16.67 8.33 
66 23.94 15.96 7.98 
67 22.90 15.27 7.63 
68 21.88 14.59 7.29 
69 20.89 13.93 6.96 
70 19.90 13.27 6.63 
71 18.96 12.64 6.32 
72 18.01 12.01 6.00 
73 17.11 11.41 5.70 
74 16.21 10.81 5.40 
75 15.36 10.24 5.12 
76 14.52 9.68 4.84 
77 13.71 9.14 4.57 
78 12.93 8.62 4.31 
79 12.16 8.11 4.05 
80 11.43 7.62 3.81 
*—Number of diseases refers to the conditions listed in the Charlson Comorbidity Index. 
Table 1b. Comorbidity-Adjusted Life Expectancy in U.S. Men  
Adverse effects vary depending on the treatment modality used; the specialist’s experience; 
the criteria used to assess the frequency, severity, and duration of symptoms and their baseline 
status; and the medications or devices used to treat the symptoms. Table 2 shows the incidence 
of adverse effects two years after surgery and EBRT. 37 Adverse effects noted five years after 
treatment include no urinary control or frequent urinary leakage (14 percent after surgery 
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versus 5 percent after EBRT, with pad use in 29 percent of surgical patients and 4 percent of 
EBRT patients). 36 After adjusting for baseline factors, dripping or leaking urine was noted six 
times more often after surgery than after EBRT.36 Erections insufficient for intercourse 
occurred in approximately three-fourths of patients after surgery or EBRT.36 Despite these 
adverse effects, less than 5 percent of patients reported dissatisfaction with treatment, and 
more than 90 percent of patients said they would make the same decision again.36 Patients 
who underwent surgery were most satisfied. Patient satisfaction was highly related with 
adverse effects, but also with the perception of freedom from prostate cancer.  
 
Adverse effect 
Watchful 
waiting (%) 
Surgery (%) 
External beam 
radiation (%) 
Hormone 
therapy (%) 
Bowel problems 
(urgency) 
16 14 29 16 
Erectile dysfunction 
(no erections at all) 
33 58 43 86 
Urinary problems 
(leaking) 
7 35 12 11 
     
Adapted from Agency for Healthcare Research and Quality. Treating prostate cancer. A guide for 
men with localized prostate cancer. 
http://www.effectivehealthcare.ahrq.gov/ehc/products/9/98/ProstateCancerConsumer.pdf 
Accessed June 4, 2010. 
Table 2. Adverse Effects Two Years After Prostate Cancer Treatment  
Compared with observation and watchful waiting, active surveillance is a more structured 
program to track the progression of prostate cancer, allowing for earlier intervention if the 
patient’s risk is found to increase on follow-up. A protocol used in Canada is shown in Table 
3 10; with the use of this protocol, patient survival is similar to that after treatment (99.2 
percent at eight years in 299 patients).10 About 25 percent of patients in this protocol proceed 
to intervention.9 Patient survival in a European study was 100 percent at 10 years in 616 
patients. 38 In this ongoing study, patients continue with active surveillance only if their PSA 
level (checked every three months) doubles in more than three years; if cancer is present in 
only one or two biopsy cores; and if their Gleason score remains 6 (3+3) or lower (biopsy is 
done if the PSA doubling time is three to 10 years, and routinely at one, three, five, and 
seven years, then every five years thereafter). Active surveillance is recommended for low- 
and very low-risk patients. Drawbacks include the potentially increased difficulty of 
curative or nerve-sparing surgery in patients for whom intervention is delayed despite 
increasing risk, and mild anxiety. However, men following this protocol have been found to 
have favorable levels of anxiety and distress.39 
In summary, with the use a new, easy and quick method that we have described to estimate 
a newly-diagnosed patient’s co-morbidity adjusted life expectancy, physicians can help 
patients in choosing treatment or observation according to evidence-based national 
guidelines. This may reduce reluctance among patients and physicians in getting PSA 
screening and may reduce worry regarding over-diagnosis of low-risk cancers and the 
potential damage to the patient’s health-related quality of life through unnecessary 
treatment of such cancers. We have recently published our algorithm in the journal 
American Family Physician, 40 which is the most widely read journal in primary care; this 
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may help primary care physicians in counseling newly-diagnosed patients; until now 
patients return to primary care physicians after they have chosen a course of treatment as 
recommended by the urologist who had done the biopsy. 41 Although in October 2011 the 
United States Preventive Services Task Force has recommended against PSA testing,42 this 
recommendation is based on the potential harms that can result from treatment of low-risk 
cancers. However, to not screen for prostate cancer- which is the second most common 
cause of cancer death in American men, will inevitably lead to even more deaths from 
untreated advanced cancer. A more prudent approach might be to screen for the cancer, but 
to use the approach in this article to convince low-risk patients to choose active surveillance 
instead of immediate treatment.     
 
Eligibility criteria 
• PSA level ≤ 10 ng per mL (10 µg per L), Gleason score of 6 or lower, and stage T1c or 
T2a cancer 
• For men with more than 15-year life expectancy: fewer than three cores and less than 
50 percent of any one core involved  
Follow-up schedule 
• PSA testing and digital rectal examination every three months for two years, then 
every six months as long as PSA level is stable 
• 10 to 12 core biopsies at one year, then every three years until 80 years of age 
• Optional: transrectal ultrasonography on alternate visits  
Indications for intervention 
• PSA doubling time less than three years (based on at least eight determinations; 
required in about 20 percent of patients) 
• Progression to Gleason score of 7 (4+3) or higher (required in about 5 percent of 
patients) 
PSA = prostate-specific antigen. Adapted with permission from Klotz L. Active Surveillance for prostate 
cancer: for whom? J Clin Oncol 2005; 23(32): 8167 
Table 3. Canadian Protocol for Active Surveillance of Prostate Cancer 
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